Efficacy of Insulin Degludec/Insulin Aspart (idegasp) Vs. Insulin Glargine (iglaru300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study

Objective: To investigate the efficacy of insulin degludec/insulin aspart (IDegAsp) co -formulation versus insulin glargine U300 (IGlarU300) in insulin -naive individuals with type 2 diabetes (T2D) who had inadequate glycemic control with three oral antidiabetic drugs. Materials and methods: In this multicenter, retrospective, observational study, insulin -naive individuals with T2D were subjected to standard care. Healthcare practitioners across this multicentric study initiated treatment with either IDegAsp (group 1) or IGlarU300 (group 2) as the insulin of choice. The participants' glycometabolic parameters, such as weight, body mass index (BMI), creatinine, hemoglobin A1c (HbA1c), fasting blood glucose (FBG), and postprandial blood glucose (PPBG) levels were analysed over 6 months. Changes in these parameters over 6 months were evaluated. Statistical significance was determined using the t -test. Results: Both treatment groups showed equivalent improvements in glycometabolic parameters, such as HbA1c, creatinine, FBG, PPBG levels, and hypoglycemic episodes over 6 months when compared to the baseline levels. Additionally, at every follow-up, the weight and BMI of both groups were similar. No severe hypoglycemic events were observed in either treatment group. Conclusions: Our findings support that IDegAsp is non -inferior to IGlarU300 and may be considered for treatment in insulin -naive people with inadequately controlled T2D as an initiation insulin option. (Clin Diabetol 2024; 13, 1: 67-75)